Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857415 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
A Phase 3 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 226
- Enrollment target
NCT00857415: Completed Phase 3 study, sponsored by Avid Radiopharmaceuticals.
NCT00857415 is a Phase 3 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 226 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00857415, a Phase 3 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 226 participants
- Enrollment target
Study Summary
The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
Primary Outcome
Spearman's rank order correlation of the median semi-quantitative visual read of the florbetapir-PET image and the amyloid plaque density assessed post-mortem by quantitative immunohistochemistry (IHC) averaged across 6 brain regions (precuneus, parietal cortex, frontal cortex, temporal cortex, posterior cingulate, anterior cingulate). Spearman's rank order correlation ranges from -1 to +1. A value of -1 indicates perfect negative correlation, and a value of +1 indicates a perfect positive corre
Interventions
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
What the finished NCT00857415 record still lists
NCT00857415 is an interventional study that assigns participants to a tested intervention. The registered 226 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 1 intervention - of which florbetapir F 18 is the first listed.
NCT00857415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00857415 about?
NCT00857415 is a clinical study titled "Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain". The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD).
What is the current status of trial NCT00857415?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 226 participants. The study started on 2008-12. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00857415?
The interventions under investigation include: florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT00857415?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00857415's enrollment target sits among peer trials
226 1310th of 2000 higher than 690 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04419272 · 226 participants · Phase 4
Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits
- NCT05449002 · 226 participants · NA
Digital Single Session Intervention for Youth Mental Health
- NCT05488054 · 226 participants · NA
Muscle O2 Saturation and Hemoglobin Levels During Rehabilitation From Arthroscopic Surgery
- NCT05924477 · 226 participants · NA
Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia